Evaluation of antimicrobial prophylaxis in genital gender affirmation surgery.

IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY American Journal of Health-System Pharmacy Pub Date : 2025-04-17 DOI:10.1093/ajhp/zxaf063
Lauren Schmidt, Mary Blair, Kerri Degenkolb, David Foster, Andrew Lodolo, Monica Macik, Taylor Rhew, Mary Soyster, Joshua Roth
{"title":"Evaluation of antimicrobial prophylaxis in genital gender affirmation surgery.","authors":"Lauren Schmidt, Mary Blair, Kerri Degenkolb, David Foster, Andrew Lodolo, Monica Macik, Taylor Rhew, Mary Soyster, Joshua Roth","doi":"10.1093/ajhp/zxaf063","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this study was to evaluate antimicrobial prophylaxis regimens for genital gender affirmation surgery in the prevention of surgical site infections and other infectious complications and to provide a descriptive report of what was observed when using the study sites' recommended regimens.</p><p><strong>Methods: </strong>This retrospective observational study was completed at 2 urban academic medical centers between June 1, 2020, and June 30, 2023. All data were collected through retrospective chart review. The primary outcome of this study was the prevalence of surgical site infections within 30 days following genital gender affirmation surgery completed by a single surgeon at 2 health centers. Secondary outcomes included the prevalence of surgical site infections within 6 months of surgery, potential relationships of demographic data and type of surgery with the development of postoperative infection, and relationships of antibiotics, dose, and number of subsequent doses with the development of postoperative infection.</p><p><strong>Results: </strong>A total of 146 surgeries (124 patients) were included in the final analysis. Surgical site infection occurred within 30 days postoperatively in 4 patients (3%), most commonly noted on the first follow-up visit within 1 month of surgery. Another 2 infections occurred within 6 months postoperatively, resulting in a total of 6 patients (4%) with surgical site infections during the study period.</p><p><strong>Conclusion: </strong>This study observed an acceptable prevalence of surgical site infections within both 30 days and 6 months of genital gender affirmation surgery. This outcome supports the use of narrow gram-positive and gram-negative coverage (ie, cefazolin) for clean and clean-contaminated procedures without entry into the gastrointestinal (GI) or gastroduodenal (GU) tracts, with the addition of anaerobic coverage (ie, metronidazole) for clean-contaminated procedures with entry into the GI or GU tract, as clinically appropriate options.</p>","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":"483-489"},"PeriodicalIF":2.3000,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Health-System Pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ajhp/zxaf063","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: The purpose of this study was to evaluate antimicrobial prophylaxis regimens for genital gender affirmation surgery in the prevention of surgical site infections and other infectious complications and to provide a descriptive report of what was observed when using the study sites' recommended regimens.

Methods: This retrospective observational study was completed at 2 urban academic medical centers between June 1, 2020, and June 30, 2023. All data were collected through retrospective chart review. The primary outcome of this study was the prevalence of surgical site infections within 30 days following genital gender affirmation surgery completed by a single surgeon at 2 health centers. Secondary outcomes included the prevalence of surgical site infections within 6 months of surgery, potential relationships of demographic data and type of surgery with the development of postoperative infection, and relationships of antibiotics, dose, and number of subsequent doses with the development of postoperative infection.

Results: A total of 146 surgeries (124 patients) were included in the final analysis. Surgical site infection occurred within 30 days postoperatively in 4 patients (3%), most commonly noted on the first follow-up visit within 1 month of surgery. Another 2 infections occurred within 6 months postoperatively, resulting in a total of 6 patients (4%) with surgical site infections during the study period.

Conclusion: This study observed an acceptable prevalence of surgical site infections within both 30 days and 6 months of genital gender affirmation surgery. This outcome supports the use of narrow gram-positive and gram-negative coverage (ie, cefazolin) for clean and clean-contaminated procedures without entry into the gastrointestinal (GI) or gastroduodenal (GU) tracts, with the addition of anaerobic coverage (ie, metronidazole) for clean-contaminated procedures with entry into the GI or GU tract, as clinically appropriate options.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
生殖器性别确认手术中抗菌预防的评价。
免责声明:为了加快文章的发表,AJHP在接受稿件后将尽快在网上发布。被接受的稿件已经过同行评审和编辑,但在技术格式化和作者校对之前会在网上发布。这些手稿不是记录的最终版本,稍后将被最终文章(按照AJHP风格格式化并由作者校对)所取代。目的:本研究的目的是评估生殖器性别确认手术的抗菌预防方案在预防手术部位感染和其他感染并发症方面的作用,并提供使用研究部位推荐方案时观察到的描述性报告。方法:本回顾性观察研究于2020年6月1日至2023年6月30日在2个城市学术医疗中心完成。所有数据均通过回顾性图表分析收集。本研究的主要结果是在2个卫生中心由一名外科医生完成生殖器性别确认手术后30天内手术部位感染的发生率。次要结局包括手术后6个月内手术部位感染的发生率,人口统计学数据和手术类型与术后感染发生的潜在关系,以及抗生素、剂量和后续剂量与术后感染发生的关系。结果:共纳入146例手术,124例患者。4例(3%)患者术后30天内发生手术部位感染,最常见于术后1个月内的首次随访。术后6个月内发生2例感染,共6例(4%)患者在研究期间发生手术部位感染。结论:本研究观察到生殖器性别确认手术30天和6个月内手术部位感染的发生率是可以接受的。该结果支持在不进入胃肠道(GI)或胃十二指肠(GU)的清洁和清洁污染的手术中使用狭窄的革兰氏阳性和革兰氏阴性覆盖(即头孢唑林),在进入胃肠道或胃十二指肠(GU)的清洁污染手术中增加厌氧覆盖(即甲硝唑),作为临床适当的选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.90
自引率
18.50%
发文量
341
审稿时长
3-8 weeks
期刊介绍: The American Journal of Health-System Pharmacy (AJHP) is the official publication of the American Society of Health-System Pharmacists (ASHP). It publishes peer-reviewed scientific papers on contemporary drug therapy and pharmacy practice innovations in hospitals and health systems. With a circulation of more than 43,000, AJHP is the most widely recognized and respected clinical pharmacy journal in the world.
期刊最新文献
Implications of pharmacy students' involvement in collecting the best possible medication histories in hospital settings: A scoping review. The role of artificial intelligence in emergency medicine pharmacy practice. Treatment disparities and health inequities in emergency medicine-A pharmacist perspective. Medication overrides: Decreasing risk through process improvement in a pediatric health system. Comprehensive pharmacy-based investigational drug service: A 40-year update.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1